Abstract
Abstract Background and Objectives: The presence of antibodies against Rh D in intravenous immunoglobulin (IVIG) products has been proposed as causing adverse reactions and blood grouping problems, although data on the incidence and titre of such antibodies is sketchy. This study was conducted to investigate methodology for carrying out haemagglutination tests on IVIG products, and to examine in retrospect 200 IVIG batches for the presence of anti‐D and other haemagglutinins. Materials and Methods: Batches of commercial IVIG products were tested using the low‐ionic‐strength indirect antiglobulin test (LIAT). Positive batches were futher investigated using a typed red cell panel and direct haemagglutination tests. Results: 44 batches of IVIG gave positive LIAT. Of these, 12 contained specific anti‐D. 11 batches had LIAT anti‐D titres of 2–8; a further batch contained anti‐D with a LIAT titre of 64. The remaining 32 batches agglutinated all erythrocyte phenotypes tested with LIAT titres ≤4; 14 of these batches showed positive direct haemagglutination and the presence of rouleaux. Conclusion: 6% of commercial IVIG batches contained specific anti‐D, including one batch (0.5%) showing unusually high titre. 16% of batches contained haemagglutinins of unknown/non‐specificity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
